---
title: "XTNT.US (XTNT.US) — Related News"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/XTNT.US/news.md"
symbol: "XTNT.US"
name: "XTNT.US"
parent: "https://longbridge.com/en/quote/XTNT.US.md"
datetime: "2026-05-21T05:35:38.174Z"
locales:
  - [en](https://longbridge.com/en/quote/XTNT.US/news.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/XTNT.US/news.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/XTNT.US/news.md)
---

# XTNT.US (XTNT.US) — Related News

### [Xtant Medical Updates Q1 Results and Raises 2026 Guidance](https://longbridge.com/en/news/286254004.md)
*2026-05-13T11:33:07.000Z*
> Xtant Medical Holdings reported Q1 2026 revenue of $20.9 million, down from $32.9 million year-over-year, with a net los

### [Xtant Med | 8-K: FY2026 Q1 Revenue Beats Estimate at USD 20.88 M](https://longbridge.com/en/news/286248416.md)
*2026-05-13T11:07:59.000Z*
### [Xtant Medical Reports First Quarter 2026 Financial Results | XTNT Stock News](https://longbridge.com/en/news/286247087.md)
*2026-05-13T03:01:04.000Z*
> Xtant Medical Reports First Quarter 2026 Financial Results | XTNT Stock News

### [Xtant Medical to Announce First Quarter 2026 Financial Results on May 13, 2026 | XTNT Stock News](https://longbridge.com/en/news/285547187.md)
*2026-05-07T04:00:00.000Z*
> Xtant Medical Holdings, Inc. (NYSE American: XTNT) will announce its financial results for Q1 2026 on May 13, 2026, befo

### [Xtant Medical Expands Trivium™ Portfolio with the Commercial Launch of Trivium™ Shaped | XTNT Stock News](https://longbridge.com/en/news/285372631.md)
*2026-05-06T04:00:35.000Z*
> Xtant Medical Expands Trivium™ Portfolio with the Commercial Launch of Trivium™ Shaped | XTNT Stock News

### [12 Health Care Stocks Moving In Wednesday's Pre-Market Session](https://longbridge.com/en/news/283663619.md)
*2026-04-22T12:05:38.000Z*
> In Wednesday's pre-market session, Axe Compute (NASDAQ:AGPU) saw a significant rise of 148.8% to $12.14, while Kyverna T

### [Xtant Medical Gains Exclusive U.S. Rights to HEMOBLAST Bellows, Pays $5.0M Fee](https://longbridge.com/en/news/282552865.md)
*2026-04-13T13:23:01.000Z*
> Xtant Medical has secured exclusive U.S. distribution rights for HEMOBLAST Bellows, paying a $5.0 million fee to Dilon.